Overview

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Status:
Completed
Trial end date:
2002-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effectiveness of various combinations of anti-HIV drugs in HIV-positive men and women. Patients receive specific combinations of 3 or 4 of the following 6 drugs: didanosine (ddI), stavudine (d4T) efavirenz (EFV), nelfinavir (NFV), lamivudine (3TC), or zidovudine (ZDV). Anti-HIV therapy is effective in preventing the spread of HIV in the body. However, patients often experience unpleasant side effects and have difficulties following the dosing schedule. This study looks for combinations of anti-HIV drugs ("cocktails") which will be the most effective with the fewest problems.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Abacavir
Amprenavir
Didanosine
Efavirenz
HIV Protease Inhibitors
Hydroxyurea
Indinavir
Lamivudine
Lamivudine, zidovudine drug combination
Nelfinavir
Protease Inhibitors
Reverse Transcriptase Inhibitors
Ritonavir
Stavudine
Zidovudine